Edwards Lifesciences Corporation EW

86.29 0.56 0.65% as of 25 Sep
Market cap
$49.4B
P/E
49.6×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Edwards Lifesciences Corporation (EW) Revenue growth

Edwards Lifesciences Corporation's revenue growth over the twelve months to 30 June 2026 was 14.6%, up 3.0 percentage points from fiscal 2025 (11.6%). Over the past ten years it has ranged from −14.7% (fiscal 2022) to 19.3% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Medical Devices industry median of 8.80% and above the Healthcare sector median of 8.26%.

Revenue growth, annual

Annual

Period Revenue growth Change (points)
FY2025 11.6% 2.98
FY2024 8.57% (3.66)
FY2023 12.2% 26.92
FY2022 −14.7% (33.98)
FY2021 19.3% 18.41
FY2020 0.88% (15.91)
FY2019 16.8% 8.42
FY2018 8.37% (7.54)
FY2017 15.9% (2.94)
FY2016 18.9% 11.50

Quarterly

Period Revenue growth Change (points)
Jun 2026 13.6% (3.07)
Mar 2026 16.7% 3.44
Dec 2025 13.3% (1.41)
Sep 2025 14.7% 2.78
42 more quarters

Against its own ten years

Low −14.7% High 19.3%
Ten-year median 11.6%
Current reading's percentile 55

Revenue growth against peers

Company Revenue growth
DXCM DexCom, Inc. compare 15.5%
EW Edwards Lifesciences Corporation 14.6%
BSX Boston Scientific Corporation compare 13.5%
MDT Medtronic PLC compare 9.77%
PHG Koninklijke Philips N.V. compare 9.11%
ZBH Zimmer Biomet Holdings, Inc. compare 8.62%
SYK Stryker Corporation compare 8.48%
STE STERIS plc compare 8.37%
GEHC GE HealthCare Technologies Inc. compare 6.51%
Medical Devices industry median 8.80%
Healthcare sector median 8.26%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on EW